Success With Celgene
What’s the ‘Fourth’ wall? Epizyme’s $25M for proof-of-concept hurdle
By Randy Osborne
Tuesday, January 7, 2014
The rebound story of the week came via Epizyme Inc., which climbed mightily on news from the Phase I trial with its EPZ-5676 DOT1L histone methyltransferase (HMT) inhibitor, hitting a proof-of-concept milestone and bringing a $25 million payment from collaborator Celgene Corp.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.